Replication of Cobenfy's clinical cognitive benefits in a schizophrenia mouse model (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR004.01 / N5; Pres time: Nov 14, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "Cobenfy, a groundbreaking combination of xanomeline and trospium, is the first FDA-approved drug for schizophrenia with a non-dopaminergic mechanism, offering a novel approach to treatment. These preclinical findings support the translational validity of the MK-801-induced cognitive deficit model and replicate the clinical cognitive benefits of Cobenfy with selectivity for cognition over positive symptom-like behaviors. Together, these results highlight the model's utility for future mechanistic investigations and preclinical evaluation of therapies targeting cognitive dysfunction in schizophrenia."
Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia
|
|
S. WAGNER; E. POIRAUD; F. LAUGA; E. ANDRIAMBELOSON
|